The journal of allergy and clinical immunology. Global · 2026
Targeting CXCR1/2 suppresses TH2/TH17 cell responses and inhibits dual-pathology allergic lung inflammation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hosoki Koa, Govindhan Annamalai, Knight John M, Sur Sanjiv
Аннотация
BACKGROUND: Many chronic inflammatory diseases are driven by TH2 and TH17 immune responses and represent a major public health burden. While monoclonal antibodies against individual TH2 or TH17 cytokines or receptors show clinical benefit, their efficacy is limited by overlapping TH2/TH17 pathology. This highlights the need to identify shared upstream pathways whose inhibition could suppress both responses simultaneously.
OBJECTIVE: We sought to elucidate the role of CXCR1/2 in recruitment and proliferation of TH2 and TH17 cells during allergic airway inflammation.
METHODS: Studies used mice sensitized and challenged with cat dander extract, inducing dual TH2/TH17 lung inflammation. Expression of TH2, TH17, CXCL, and CXCR was quantified, and ex vivo CXCL stimulation of lung single-cell suspensions was used to assess TH2 and TH17 proliferation.
RESULTS: Allergen challenge upregulated Cxcl1/2/3/5 mRNA, and increased CXCR1/2+ TH2 and TH17 cells in lung single-cell suspensions. Ex vivo stimulation of these suspensions with a CXCL1/2/3/5 cocktail induced CXCR1/2-dependent proliferation of IL-4+, IL-5+, IL-13+, and IL-17+ T cells. In vivo, allergen challenge increased CXCR1/2-dependent accumulation of CXCR1+ and CXCR2+ TH2 and TH17 cells in the lungs, upregulated I l 6 and Il23 expression in granulocytes/cytokines that support TH17 responses, and exacerbated eosinophilic lung inflammation. Concurrent CXCR1 and CXCR2 blockade effectively abrogated or attenuated these effects on dual TH2/TH17 allergic inflammation.
CONCLUSIONS: CXCL chemokines play a novel role in driving proliferation of CXCR1+/CXCR2+ TH2/TH17 cells, thereby promoting overlapping TH2/TH17 lung inflammation. Targeting the CXCL-CXCR1/2 axis may provide a new strategy for treating dual TH2/TH17 diseases.
OBJECTIVE: We sought to elucidate the role of CXCR1/2 in recruitment and proliferation of TH2 and TH17 cells during allergic airway inflammation.
METHODS: Studies used mice sensitized and challenged with cat dander extract, inducing dual TH2/TH17 lung inflammation. Expression of TH2, TH17, CXCL, and CXCR was quantified, and ex vivo CXCL stimulation of lung single-cell suspensions was used to assess TH2 and TH17 proliferation.
RESULTS: Allergen challenge upregulated Cxcl1/2/3/5 mRNA, and increased CXCR1/2+ TH2 and TH17 cells in lung single-cell suspensions. Ex vivo stimulation of these suspensions with a CXCL1/2/3/5 cocktail induced CXCR1/2-dependent proliferation of IL-4+, IL-5+, IL-13+, and IL-17+ T cells. In vivo, allergen challenge increased CXCR1/2-dependent accumulation of CXCR1+ and CXCR2+ TH2 and TH17 cells in the lungs, upregulated I l 6 and Il23 expression in granulocytes/cytokines that support TH17 responses, and exacerbated eosinophilic lung inflammation. Concurrent CXCR1 and CXCR2 blockade effectively abrogated or attenuated these effects on dual TH2/TH17 allergic inflammation.
CONCLUSIONS: CXCL chemokines play a novel role in driving proliferation of CXCR1+/CXCR2+ TH2/TH17 cells, thereby promoting overlapping TH2/TH17 lung inflammation. Targeting the CXCL-CXCR1/2 axis may provide a new strategy for treating dual TH2/TH17 diseases.